Unresectable colorectal cancer primary or metastatic lesions: training set
Summary:
Analysis of primary or metastatic lesions from patients with unresectable colorectal cancer (CRC) prior to FOLFOX6 therapy (oxaliplatin, 5-fluorouracil, leucovorin regimen). Results provide insight into molecular signatures that predict responders to FOLFOX therapy for unresectable CRC.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Tsuji S, Midorikawa Y, Takahashi T, Yagi K et al. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br J Cancer 2012 Jan 3;106(1):126-32. PMID: 22095227
